BioWorld MedTech

July 23, 2015

View Archived Issues

St. Jude, Thoratec show a lot of Heart in transaction: St. Jude shows it has 'heart' with proposed $3.4B Thoratec acquisition

St. Jude Medical (NYSE:STJ) (St. Paul, Minn.) said that it has agreed to acquire Thoratec (NASDAQ:THOR) (Pleasanton, Calif.) for $63.50 per share in a cash transaction valued at about $3.4 billion. Read More

Inside the Beltway: Harmonization of GCPs seen as sticking point for OUS trials draft

Read More

Government programs still solvent: Balancing act: Trustees say Part A trust fund solvent through 2030

Read More

India's first materiovigilance program: India launches first program to track adverse effects of devices

Read More

BSX Initiates Fast Study: New generation bioabsorbable scaffolds may challenge DES

Read More

Financings: MedGenome receives $20M investment in Series B round

Read More

Agreements/contracts: Syngnis pulls a Double Switch with Thermo Fisher Scientific

Read More

People in places

Read More

Product briefs

Read More

Briefly Noted

Read More

MDD's Orthopedics Extra

Read More